Your browser doesn't support javascript.
loading
Optimizing maturity-onset diabetes of the young detection in a pediatric diabetes population.
Menon, Sruthi; Refaey, Ahmad; Guffey, Danielle; Balasubramanyam, Ashok; Redondo, Maria J; Tosur, Mustafa.
Afiliação
  • Menon S; Department of Pediatrics, Division of Diabetes and Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
  • Refaey A; University of Houston, Houston, Texas, USA.
  • Guffey D; Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
  • Balasubramanyam A; Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas, USA.
  • Redondo MJ; Department of Pediatrics, Division of Diabetes and Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
  • Tosur M; Department of Pediatrics, Division of Diabetes and Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
Pediatr Diabetes ; 23(4): 447-456, 2022 06.
Article em En | MEDLINE | ID: mdl-35218126
ABSTRACT

INTRODUCTION:

Maturity-onset diabetes of the young (MODY) is often misdiagnosed as type 1/type 2 diabetes. We aimed to define patient characteristics to guide the decision to test for MODY in youth with diabetes. RESEARCH DESIGN AND

METHODS:

Of 4750 patients enrolled in the Diabetes Registry at Texas Children's Hospital between July 2016 and July 2019, we selected ("Study Cohort", n = 350) those with (1) diabetes diagnosis <25 years, (2) family history of diabetes in three consecutive generations, and (3) absent islet autoantibodies except for GAD65. We retrospectively studied their clinical and biochemical characteristics and available MODY testing results. Cluster analysis was then performed to identify the cluster with highest rate of MODY diagnosis.

RESULTS:

Patients in the Study Cohort were 3.5 times more likely to have been diagnosed with MODY than in the overall Diabetes Registry (4.6% vs. 1.3%, p < 0.001). The cluster (n = 16) with the highest rate of clinician-diagnosed MODY (25%, n = 4/16) had the lowest age (10.9 ± 2.5 year), BMI-z score (0.5 ± 0.9), C-peptide level (1.5 ± 1.2 ng/ml) and acanthosis nigricans frequency (12.5%) at diabetes diagnosis (all p < 0.05). In this cluster, three out of five patients who underwent MODY genetic testing had a pathogenic variant.

CONCLUSIONS:

Using a stepwise approach, we identified that younger age, lower BMI, lower C-peptide, and absence of acanthosis nigricans increase likelihood of MODY in racially/ethnically diverse children with diabetes who have a multigenerational family history of diabetes and negative islet autoantibodies, and can be used by clinicians to select patients for MODY testing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Acantose Nigricans Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Adolescent / Child / Humans Idioma: En Revista: Pediatr Diabetes Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Acantose Nigricans Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Adolescent / Child / Humans Idioma: En Revista: Pediatr Diabetes Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos